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Germline mutations in the phosphatase and tensin homolog (PTEN)
gene manifest in a spectrum of autosomal dominant disorders, the
most common of which is Cowden syndrome (CS), but also include
Bannayan–Riley–Ruvalcaba syndrome, adult Lhermitte–Duclos disease,
macrocephaly, and autism spectrum disorders (Pilarski et al., 2013). CS
was ﬁrst described in 1963 (Lloyd and Dennis, 1963) and PTEN gene mu-
tationswereﬁrst described in patientswith CS in 1997 (Nelen et al., 1997;
Liaw et al., 1997). Loss of functionmutations in PTEN, a tumor suppressor
gene, results in oncogenesis through negative regulation of themTOR sig-
naling pathway.Mutations in PTEN are rare,with an estimated prevalence
of 1 in 200,000 to 250,000 (Nelen et al., 1999).
Patients with PTEN mutations commonly present with hamar-
tomatous lesions involving multiple organ systems. In 2013 Pilarski
et al. proposed updated diagnostic criteria for CS, concluding that there
was insufﬁcient evidence to include uterine ﬁbroids, benign breast
disease, or genitourinary malformations in the diagnostic criteria
(Pilarski et al., 2013); clinical diagnosis is suspected based on satisfying
updated major and minor criteria (Table 1). Importantly, patients with
CS have an estimated lifetime risk for invasive carcinomas of the breast
(85%), thyroid (35%), endometrium (28%), colon (9%), and kidney (34%),bjects for
dometrial
the time of
sity at the
e patient's
oncogene-
through a
Case report
A healthy 40 year-old nulliparous female had multiple 2–3 mm
papules on the face, forehead, and chin present since 8 years old. Biopsy
suggested trichilemmoma and she was referred to medical genetics
for further evaluation. Physical examination showed macrocephaly,
stippled café-au-lait spots, and punctated dells involving the palms.
She had recently undergone uterine artery embolization for a
12 cm uterine leiomyoma. The patient had no family history of CS.
Genetic testing for PTEN mutations identiﬁed a deleterious PTEN
mutation (N48K).
Endometrial biopsy (EMB) was negative for neoplasia. Screening
breast MRI demonstrated a suspicious mass, and MRI-guided biop-
sy revealed atypical ductal hyperplasia. The patient underwent a coordi-
nated risk-reducing total abdominal hysterectomy, bilateral salpingo-
oophorectomy, and left breast excisional biopsy without complication.
Pathology revealed multiple areas of atypical ductal hyperplasia of the
left breast, but no in-situ or invasive carcinoma. The uterus weighed
438 g, including a 9 cm fundalﬁbroid, and pathology showed endometrial
neoplasmwith features of complex atypical hyperplasia. Two years later,
bilateral breastMRI identiﬁed additional abnormalities,with core biopsies
revealingmultifocal atypical ductal hyperplasia. Thepatient elected for bi-
lateral risk reducing mastectomies. Pathology revealed scattered foci of
atypical ductal hyperplasia and atypical lobular hyperplasia.
Molecular testing of tissue specimens
Thepatient participated in an IRB approved tissue bank providing for
collection and molecular evaluation of surgical specimens. DNA was
Table 1
Revised Cowden syndrome/PTEN hamartoma tumor syndrome clinical diagnostic criteria
(adapted from Pilarski et al., 2013).
Operational diagnosis in an individual (either of the following)
1. Three or more major criteria, but one must include macrocephaly,
Lhermitte–Duclos disease, or gastrointestinal hamartomas; or
2. Two major and three minor criteria
Operational diagnosis in a family where one individual meets revised PTEN
hamartoma tumor syndrome clinical diagnostic criteria or has a PTENmutation:
1. Any two major criteria with or without minor criteria; or
2. One major and two minor criteria; or
3. Three minor criteria
Major criteria
Breast cancer
Endometrial cancer (epithelial)
Thyroid cancer (follicular)
Gastrointestinal hamartomas (including ganglioneuromas, but excluding
hyperplastic polyps; ≥3)
Lhermitte–Duclos disease (adult)
Macrocephaly (≥97th percentile: 58 cm for females, 60 cm for males)
Macular pigmentation of the glans penis
Multiple mucocutaneous lesions (any of the following):
Multiple trichilemmomas (≥3, at least one biopsy proven)
Acral keratoses (≥3 palmoplantar keratotic pits and/or acral hyperkeratotic
papules)
Mucocutaneous neuromas (≥3)
Oral papillomas (particularly on tongue and gingiva), multiple (≥3) OR biopsy
proven OR dermatologist diagnosed
Minor criteria
Autism spectrum disorder
Colon cancer
Esophageal glycogenic acanthosis (≥3)
Lipomas (≥3)
Mental retardation (i.e., IQ ≤ 75)
Renal cell carcinoma
Testicular lipomatosis
Thyroid cancer (papillary or follicular variant of papillary)
Thyroid structural lesions (e.g., adenoma, multinodular goiter)
Vascular anomalies (including multiple intracranial developmental venous
anomalies)
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normal epithelial populations obtained from formalin-ﬁxed parafﬁn-
embedded specimens of both normal and neoplastic breast and endo-
metrial tissue using laser capture microdissection. Sanger sequencing
of the known PTENmutationwas performed to identify loss or retention
of the mutant andwildtype alleles by comparing normalized peak ﬂuo-
rescent heights. Non-neoplastic breast and endometrial epithelium and
stroma retained both PTEN alleles (Fig. 1). In contrast, atypical breast
and endometrial epithelium demonstrated loss of the wildtype allele,
the pattern typically seen in invasive cancers associated with tumor
suppressor genes, providing support that both the atypical hyperplasia
in the endometrium and breast were neoplastic and precursors to inva-
sive carcinoma.Discussion
Cowden syndrome is characterized by a signiﬁcantly increased
risk of multiple cancers, but the natural history of cancer develop-
ment has not been documented. Our patient's deleterious germline
mutation in PTEN (N48K) is a missense mutation that impairs the
ability of the mutant PTEN protein to inhibit PKB/Akt activation
(Vega et al., 2003). In our analysis of endometrium and breast
tissues, we identiﬁed loss of the wildtype PTEN allele in the atypical
hyperplasia of both sites (Fig. 1). These data support the hypotheses
that N48K is pathogenic and that aberrant PTEN function drove the
development of atypical hyperplasia/intraepithelial neoplasm in
both breast and endometrium. We believe that this is the ﬁrst dem-
onstration of the in vivo process of neoplastic transformation in
breast and endometrial epithelium in women with PTENmutations,which, in at least some cases, appears to progress through an identi-
ﬁable pre-invasive precursor.
Identiﬁcation of loss of the wildtype allele could be used to conﬁrm
the neoplastic nature of hyperplastic lesions in individuals with PTEN
mutations in cases of pathological uncertainty. Given the ﬁnding of inci-
dental endometrial hyperplasia/neoplasia at hysterectomy, we propose
that prophylactic hysterectomy specimens from women at high-risk
should be evaluated by thorough pathological sampling of the endome-
trium to exclude the presence of an occult carcinoma which might re-
quire further evaluation or treatment. Patients presenting with clinical
features of CS and complex atypical hyperplasia/endometrial cancer
should be offered germline testing for PTENmutations rather than tissue
testing, as somatic PTENmutations are common in the pathogenesis of
endometrial cancer. Identiﬁcation of a germlinemutation carries signif-
icant implications for counseling, surveillance, and recommendations
for prophylactic surgery.
The National Comprehensive Cancer Network recommends edu-
cating patients with CS about breast and endometrial cancer screen-
ing (Table 2). Patients should undergo clinical breast exams and
annual mammography, as well as breast MRI starting at age 30–35,
or 5–10 years before the earliest age of familial breast cancer (Daly
et al., 2014). Endometrial cancer screening guidelines encourage pa-
tient awareness and prompt recognition of symptoms. In addition,
providers may consider annual ultrasound and/or EMB. However,
the sensitivity of random EMB in asymptomatic women is not well
deﬁned. Several studies have investigated the role of surveillance
for gynecologic cancers in women with Lynch syndrome (LS) sum-
marized in a recent review (Auranen and Joutsiniemi, 2011).
Women with LS also have an elevated lifetime risk of endometrial
cancer of approximately 40–60% (Schmeler and Lu, 2008). Of the
ﬁve included studies, only one was prospective and none were
randomized; studies that performed routine endometrial sampling
at screening visits had the highest rate (5–6.5%) of detecting pathol-
ogy (Auranen and Joutsiniemi, 2011). However, random sampling
did not prevent the occurrence of all interval cancers. At present,
there is no data demonstrating that routine EMB in women with LS
or CS syndrome impacts survival.
Given the high rate of endometrial cancer in women with CS, it
is reasonable to offer annual screening for endometrial cancer in
women with CS using annual ultrasound and/or EMB, similar to
LS. Interestingly, our patient had a negative preoperative EMB
but surgical pathology revealed endometrial neoplasm (CAH),
supporting the hypothesis that the sensitivity of an EMB for
detecting neoplasia in asymptomatic women is less than that in
women experiencing abnormal vaginal bleeding. Similarly, endo-
metrial screening in asymptomatic breast cancer patients taking
tamoxifen with routine transvaginal ultrasound, EMB, or both
was not more effective than evaluation at the time of abnormal
bleeding (Bertelli et al., 1998; Fung et al., 2003). Given the un-
certainty over the efﬁcacy of endometrial cancer screening in
asymptomatic women, a cornerstone of preventive gynecologic
care for women with CS and LS should be careful patient educa-
tion on the recognition of abnormal uterine bleeding and the
need for prompt evaluation of new symptoms with EMB.
Among premenopausal women with CS who elect for risk-
reducing hysterectomy after completing childbearing, how should
they be counseled regarding oophorectomy? Patients with CS are
not at elevated risk of ovarian cancer and the ovaries may be safely
retained. However, among women who decline mastectomy in
favor of intensive breast cancer surveillance, oophorectomy likely
reduces breast cancer risk. Prior large prospective studies in
women with BRCA1 and BRCA2 mutations, who have a similarly
high breast cancer risk, demonstrated the beneﬁt of oophorectomy
on breast cancer incidence and mortality (Rebbeck et al., 2002;
Kauff et al., 2002; Domchek et al., 2006). Given the lack of speciﬁc
prevention data in CS, discussion of oophorectomy should be an
Table 2
Recommendations for breast and endometrial cancer risk management in Cowden
Syndrome (adapted from Daly et al., 2014).
Breast
Annual mammography and breast MRI beginning age 30–35 or 5–10 years before
earliest breast cancer diagnosis in family
Consideration of bilateral risk reducing mastectomy
Endometrium
Educate patient on symptoms of endometrial neoplasia and need for prompt
evaluation of abnormal bleeding
Consideration of annual transvaginal ultrasound and/or endometrial biopsy
Fig. 1. A. Hematoxylin and eosin (H&E) stained section of complex atypical hyperplasia of the endometrium identiﬁed incidentally at prophylactic hysterectomy. B. H&E stained section
from excisional breast biopsy demonstrating atypical hyperplasia. C–H. Sanger sequencing traces of PTEN at the site of the N48Kmutation, c.144CNA, identiﬁed with arrow. C. Loss of the
wildtype PTEN allele in DNA from microdissected epithelium from complex endometrial hyperplasia. D. Retention of both wildtype and mutant PTEN alleles in normal endometrial
epithelium and in normal endometrial stroma (E). F. Loss of the wildtype PTEN allele in DNA from microdissected epithelium atypical breast hyperplasia. G. Retention of both wildtype
and mutant PTEN alleles in normal breast epithelium and in normal breast stroma (H).
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hysterectomy, our patient had a new diagnosis of breast atypical
hyperplasia, further elevating her breast cancer risk. She was
not interested in bilateral mastectomy, but wished to otherwise
maximize her breast cancer risk reduction and thus elected bilater-
al oophorectomy. Tamoxifen is often advocated for chemopreven-
tion in women with atypical ductal hyperplasia of the breast but
should probably be avoided in CS patients with intact uteri, given
the already elevated risk of endometrial cancer.
In summary, we present an informative case demonstrating the
in vivo process of malignant transformation in a patient with Cowden
syndrome. Loss of heterozygosity at the PTENmutation in endometrium
and breast suggests that PTEN-driven oncogenesismay proceed through
a stage of pre-invasive intra-epithelial neoplasia. Thorough pathological
sampling of breast and endometrium is indicated at the time of prophy-
lactic surgery.Conﬂict of interest
The authors have nothing to disclose.
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